Yaral Pharma Unleashes Greater Commercial Potential with EVERSANA Partnership for Generics Portfolio Expansion.

Yaral Pharma, the US generics subsidiary of IBSA, is proud to partner with Eversana®, a leader in global life sciences services to help broaden its portfolio of pain and endocrinology products in the U.S. The expanding partnership with Eversana brings access to a full set of solutions to ensure top tier customer service, with third-party logistics and critical operations support at the forefront.

At Yaral Pharma, our goal is to provide exceptional customer service. We are delighted to announce that we have partnered with EVERSANA to help us reach this goal. Our initial collaboration has been extremely successful, and we are confident that EVERSANA’s expertise and commitment to excellence will continue to be invaluable as we expand our portfolio. We look forward to continuing this relationship and working together to ensure our customers receive the highest levels of performance.

We are delighted to join forces with Yaral Pharma and lend our expertise in helping to assure their medications are safely and affectionately distributed across the United States. EVERSANA is committed to delivering optimal safety and quality standards, and we are enthusiastic to partner with Yaral to deliver this. With our aid, Yaral can confidently expect a seamless and trustworthy distribution of their medications across the country.

Yaral Pharma’s launch of its first authorized generic (AG) medicated patch earlier this year was a major milestone—a prescription, nonsteroidal anti-inflammatory (NSAID) patch used to provide relief from muscle strains, sprains, and contusions. As a company committed to providing affordable, complex generic medications and improving how people access them, their lead product has already made a significant impact in the U.S. and its territories.

EVERSANA has proved to be a trust-worthy 3PL partner for Yaral Pharma, showing exceptional performance with their most recent launch of a non-opioid pain product. They provided accelerated customer set up and delivered 100% on-time, in-full product to customers. Vice President for Supply Chain and Logistics, Bill Punia, praised EVERSANA for displaying superior supply chain performance.

Yaral Pharma is positioned to skyrocket with up to three new products launching this year. These offerings have the potential to revolutionize the way therapeutics are delivered, as they explore and expand OSD, complex, and 505(b)2 offerings with a focus on the areas of pain, endocrinology, rheumatology, human reproduction, and dermo-aesthetics. Stay up-to-date on all the latest news regarding the expansive growth of Yaral Pharma.

About Yaral Pharma

Yaral Pharma Inc. is a U.S. generics subsidiary of global pharmaceutical powerhouse IBSA, located in Switzerland. The company takes pride in its commitment to making healthcare more accessible by providing authorized generics and complex generic medicines at affordable prices. Moreover, healthcare professionals and customers

Leave a Comment